Histogen Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2014-11-12: Form 8-K; Period of report 2014-11-12; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2014-10-08: Form 8-K; Period of report 2014-10-08; Description 8.01 Other Events; Details 8.01.
- 2014-09-02: Form 8-K; Period of report 2014-09-02; Description 7.01 Regulation FD Disclosure; Details 7.01.
- 2014-08-13: Form 8-K; Period of report 2014-08-13; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2014-11-12 | 8-K | 2014-11-12 | 2.02 Results of Operations and Financial Condition | 2.02 On November 12, 2014, Conatus Pharmaceuticals Inc. issued a press release announcing its financial results for the quarter and nine months ended September 30, 2014. | f8k_111214.htm |
| 2014-10-08 | 8-K | 2014-10-08 | 8.01 Other Events | 8.01 On October 8, 2014, Conatus Pharmaceuticals Inc. (the “Company”) announced that its late-breaking abstract was accepted for a poster presentation at The Liver Meeting®, the annual meeting of the American Association for the Study of Liver Diseases (“AASLD”) in Boston November 7-11, 2014. | f8k_100814.htm |
| 2014-09-02 | 8-K | 2014-09-02 | 7.01 Regulation FD Disclosure | 7.01 Steven J. Mento, Ph.D., President and Chief Executive Officer of Conatus Pharmaceuticals Inc. (“Conatus”), and other executive officers will be presenting an updated corporate presentation at various upcoming meetings beginning on September 4, 2014. | f8k_090214.htm |
| 2014-08-13 | 8-K | 2014-08-13 | 2.02 Results of Operations and Financial Condition | 2.02 On August 13, 2014, Conatus Pharmaceuticals Inc. issued a press release announcing its financial results for the quarter and six months ended June 30, 2014. | f8k_081314.htm |
| 2014-06-23 | 8-K | 2014-06-19 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 Conatus Pharmaceuticals Inc. (the “Company”) held its annual meeting of stockholders on June 19, 2014. | f8k_062314.htm |
| 2014-05-13 | 8-K | 2014-05-13 | 2.02 Results of Operations and Financial Condition | 2.02 On May 13, 2014, Conatus Pharmaceuticals Inc. issued a press release announcing its financial results for the quarter ended March 31, 2014. | f8k_051314.htm |
| 2014-04-16 | 8-K | 2014-04-14 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On April 14, 2014, Paul Klingenstein notified the board of directors (the “Board”) of Conatus Pharmaceuticals Inc. (the “Company”) that he would be resigning from the Board, effective as of April 15, 2014. | d712467d8k.htm |
| 2014-03-27 | 8-K | 2014-03-27 | 2.02 Results of Operations and Financial Condition | 2.02 On March 27, 2014, Conatus Pharmaceuticals Inc. issued a press release announcing its financial results for the quarter and year ended December 31, 2013. | document.htm |
| 2014-02-10 | 8-K | 2014-02-07 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Effective as of February 7, 2014, upon the recommendation of the nominating and corporate governance committee, and pursuant to the bylaws of Conatus Pharmaceuticals Inc. (the “Company”), the Board of Directors (the “Board”) of the Company appointed Preston S. Klassen, M.D., M.H.S. and Daniel L. Kisner, M.D. to the Board. | d673378d8k.htm |